Piper Sandler Starts Incyte (INCY) at Overweight on diversification into dermatology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Potential for growth has Piper Sandler starting Incyte (INCY) at Overweight
January 31, 2023 11:42 AM ESTPiper Sandler initiated coverage of Incyte (NASDAQ: INCY) with an Overweight rating and $100.00 price target as analyst Allison Bratzel sees potential growth in the companys venture into the dermatology space.
For the past 7+ years, the Incyte corporations shares have been somewhat range-bound. However, Bratzel believes that the revenue expectations surrounding the companys topical ruxolitinib product, Opzelura are too low for 2023 and the out-years. Bratzel opinion is supported by extensive dermatologist survey... More
